Axsome Therapeutics
AXSM
129.36
-6.32
-4.66%
Axsome Therapeutics
US · AXSM
#1533 by market cap
Listed 2015
129.36
-6.32
-4.66%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Truist Financial Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $285Market Newswire · 2026/9/23
-
Rating change
H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)TipRanks · 2026/9/22
-
Rating change
Deutsche Bank Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $267Market Newswire · 2026/9/29
-
Rating change
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251Market Newswire · 2026/9/25
-
Rating change
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $268Market Newswire · 2026/10/15
-
Rating change
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256Market Newswire · 2026/10/1
-
Rating change
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $238Market Newswire · 2026/10/26
-
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $220 to $256Market Newswire · 2026/11/4
-
Rating change
BMO Capital Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $310Market Newswire · 2026/10/12
-
Rating change
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $284Market Newswire · 2026/10/29
-
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $235 to $305Market Newswire · 2026/11/3
-
Rating change
Oppenheimer Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $280Market Newswire · 2026/10/6
-
Rating change
Oppenheimer Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $280Market Newswire · 2026/10/29
-
Rating change
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $295Market Newswire · 2026/10/8
-
Rating change
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $295Market Newswire · 2026/10/14
-
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $272Market Newswire · 2026/11/4
-
Rating change
BofA Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $276Market Newswire · 2026/10/9
-
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290Market Newswire · 2026/11/9
-
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Cuts Target Price to $223Market Newswire · 2026/11/13
-
Rating change
Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (STLN), Axsome Therapeutics (AXSM) and Contineum Therapeutics, Inc. Class A (CTNM)TipRanks · 2026/10/14
-
Rating change
BMO Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310Market Newswire · 2026/9/14
-
Rating change
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258Market Newswire · 2026/9/18
-
Rating change
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $316Market Newswire · 2026/9/12
-
Rating change
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $297Market Newswire · 2026/9/18
-
Rating change
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290Market Newswire · 2026/9/25
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Axsome Therapeutics discussion 0 comments